Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
about
Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trialsAndrogen deprivation therapy as backbone therapy in the management of prostate cancerCotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status.Enzalutamide and sleep apnea: an emerging central nervous system side-effect?Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer.Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis.Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression
P2860
Q26785658-B4319970-2FC7-4623-B289-2C8451D18707Q28071795-576B4CAB-3F13-4455-ABA5-45F4DFC193EEQ30276399-EF3717A4-920D-4091-9FE0-C435E67AF6AEQ38722189-CFFF811E-7509-45E8-8EBB-AD5D0E77C9A2Q38841082-C8942BD2-7323-4D83-B16D-939FEECD844EQ41488394-5276828F-5BC6-4B74-A86D-1B4AD540CE3CQ47929499-6E56DDA6-0298-4302-9BD4-FDEA7AAEE020Q48277880-7B27E3E1-8C60-46B0-A2A1-CFEBEE552178Q52744336-8CE0F8EC-9630-46B7-929A-D496DBEACF18Q59132279-BA1643EA-003A-49DF-962B-A3EC37AB0F20
P2860
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@ast
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@en
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@nl
type
label
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@ast
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@en
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@nl
prefLabel
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@ast
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@en
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@nl
P2093
P2860
P921
P356
P1476
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
@en
P2093
Alejo Rodriguez-Vida
Cora N Sternberg
Myria Galazi
Sarah Rudman
Simon Chowdhury
P2860
P304
P356
10.2147/DDDT.S69433
P407
P5008
P577
2015-06-29T00:00:00Z